About Univercells
Univercells is a company based in Charleroi (Belgium) founded in 2013 by Jose Castillo. Univercells has raised $150.64 million across 10 funding rounds from investors including KKR, Korea Investment Holdings and Gates Foundation. The company has 87 employees as of December 31, 2023. Univercells has completed 1 acquisition, including SynHelix. Univercells operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Charleroi, Belgium
- Employees 87 as on 31 Dec, 2023
- Founders Jose Castillo
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Univercells Sa
-
Annual Revenue
$22.55 M (USD)39as on Dec 31, 2022
-
Net Profit
-$7.12 M (USD)19as on Dec 31, 2022
-
EBITDA
-$7.12 M (USD)19as on Dec 31, 2022
-
Total Equity Funding
$150.64 M (USD)
in 10 rounds
-
Latest Funding Round
$43.33 M (USD), Series D
Oct 19, 2022
-
Investors
KKR
& 19 more
-
Employee Count
87
as on Dec 31, 2023
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Univercells
Unlock access to complete
Funding Insights of Univercells
Univercells has successfully raised a total of $150.64M across 10 strategic funding rounds. The most recent funding activity was a Series D round of $43.33 million completed in October 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Univercells
Univercells has secured backing from 20 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include KKR, Korea Investment Holdings and Gates Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital is deployed for global health technology innovations.
|
Locked | Locked | Locked | |
|
AdBio Partners is engaged in early-stage life sciences investments.
|
Locked | Locked | Locked | |
|
Venture capital is provided by TCD Capital to scale-ups.
|
Locked | Locked | Locked |
Investor details for Univercells
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Univercells
Univercells has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include SynHelix.
Investment portfolio details for Univercells
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Enzyme-based DNA synthesis technology is developed for large-scale production.
|
Locked | Locked | 2019 | Locked |
Complete acquisition details for Univercells
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Univercells
Detailed financials for Univercells
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Univercells Comparisons
Peer comparison for Univercells
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Univercells
Univercells operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
Detailed competitors of Univercells
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Univercells
Complete news archive for Univercells
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Univercells
Univercells was founded in 2013 and raised its 1st funding round 2 years after it was founded.
Univercells is headquartered in Charleroi, Belgium. It is registered at Charleroi, Walloon Region, Belgium.
Univercells is a funded company, having raised a total of $150.64M across 10 funding rounds to date.
As of Dec 31, 2023, the latest employee count at Univercells is 87.
Annual revenue of Univercells is $22.55M as on Dec 31, 2022.
Univercells was established in 2013 in Charleroi, Belgium, to focus on biomanufacturing technologies for the biopharma sector. Instrument systems have been developed for producing antibodies, proteins, and vaccines. Proprietary platforms, including the Scale-X bioreactor and Nevoline, are utilized for upstream processing of viral products. These technologies support the delivery of viral vaccines and gene therapies through scalable bioprocessing solutions.
Univercells's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Univercells has made 1 acquisition, including SynHelix.
Univercells has 20 investors. Key investors include KKR, Korea Investment Holdings, Gates Foundation, European Investment Bank, and Farallon Capital Management.